Stephen Foley: Lawyers fight it out with directors, and never mind the shareholders
Stephen Foley is a former Associate Business Editor of The Independent, based in New York. He left in August 2012. In a decade at the paper, he covered personal finance, the UK stock market and the pharmaceuticals industry, and had also been the Business section's share tipster. Between arriving with three suitcases in Manhattan in January 2006 and his departure, he witnessed and reported on a great economic boom turning spectacularly to bust. In March 2009, he was named Business and Finance Journalist of the Year at the British Press Awards.
Saturday 28 January 2012
US Outlook: As the late Steve Jobs faced up to his diagnosis of cancer and tried to face down the disease, he reached for the highest of hi-tech measures: he sequenced his entire DNA.
Our genetic make-up holds clues that can help us to understand the risks and the development of our diseases – cancer in particular, it seems – and therefore can help doctors to choose the drugs that have the best shot at working. It could not save the founder of Apple, but it has helped to shrink the tumours and lengthen the lives of many others.
The Apple founder was so optimistic about the technology, he told his biographer that he would be the first person to outrun pancreatic cancer, or among the last to die from it. But Mr Jobs was a visionary, always ahead of his time.
Desperate cancer patients of considerably less means than Mr Jobs are paying out of pocket to have their genes sequenced. Companies such as 23andme –which gets a lot of publicity because its founder is Anne Wojcicki, wife of Google founder Sergey Brin – are trying to popularise genetic testing for people interested in their ancestry as well as their health. The technology is getting closer and closer to the doctor's surgery, and private health insurers in the US are under increasing pressure to fund more uses for gene sequencing.
So you didn't need to be a Jobsian visionary to foresee a takeover battle for the San Diego gene sequencing company Illumina. That battle finally broke out this week, when Roche, the Swiss pharmaceuticals giant, launched a $5.7bn hostile bid for the company.
I wouldn't expect a quick resolution to this one. Illumina hasn't just rejected the offer, it has also installed a poison pill defence so that any stakebuilding by Roche will be offset by the issue of massive amounts of new stock. Outrageous as they may be, poison pills are still legal in the US.
On the other side, class action lawyers are rounding up shareholders for a legal action against the Illumina board, accusing directors of self-servingly rejecting a premium offer just so they can keep their jobs. Yes, this the US: it's directors vs lawyers, and sod what the shareholder wants.
Illumina shareholders have been wobbling on their commitment to the company. For the moment, the bulk of its business is selling machines and associated supplies to universities and research hospitals, since the bulk of sequencing work is still at the research level rather than for personal diagnostics. That will change in time, but until then the company is suffering from the squeeze on budgets in the public sector.
That is why Severin Schwan, Roche's chief executive, has pounced now. Roche and Illumina are ideal partners for the long run. Roche has been a pioneer in personalised medicine, because it has both a drug development and a diagnostic testing business. As the maker of some of the world's most successful cancer drugs, including Avastin and Herceptin, it has more expertise on this subject than any company, while its diagnostics division has the salesforce to push future generations of Illumina products. In other words, it can afford more than the 18 per cent premium it is offering to Illumina's depressed December share price.
Mr Schwan should pay up. That is what a visionary would do.
David Cameron stung by jellyfish: PM hurt after ignoring advice of locals while on holiday
South Korea ferry: Vice principal rescued from sinking ship found hanged
Oscar Pistorius trial: The case against Oscar Pistorius – and why the prosecution claims his story doesn't add up
Peaches Geldof funeral: Private ceremony to be held at same place as her mother Paula Yates on Easter Monday
Shropshire criminals ‘using unmanned drones and infrared cameras to find illegal cannabis farms’ – and then steal from the growers
The food poverty scandal that shames Britain: Nearly 1m people rely on handouts to eat – and benefit reforms may be to blame
US Navy christens huge $3 billion destroyer ship USS Zumwalt that appears as a fishing boat on enemy radar
Scottish independence: It is the English who should be on their knees, begging the Scots to vote ‘No’
Nigel Farage fatigue? Half of voters ‘immune’ to Ukip’s appeal
Nigel Farage on Have I Got News For You: Ukip leader ridiculed over expenses and party 'fruitcakes'
Nigel Farage: I’m taking on the status quo, and the Establishment’s fighting back
- 1 Are you turning into your dad? The top ten signs you've embraced dad-ism revealed as survey says 38 is age men turn into their father
- 2 Overheard in Waitrose: documenting the chatter in 'Britain's poshest supermarket'
- 3 Video of British Muslims dancing to Pharrell Williams's hit Happy attacked as 'sinful'
- 4 24 people applied for the 'world's toughest job', here are their interviews
- 5 Grace Dent on TV: Game of Thrones has jumped the shark
iJobs Money & Business
£150.00 per week: QA Apprenticeships: This company has been providing on site ...
£221.25 per week: QA Apprenticeships: This company is a well established Inter...
£40000 - £50000 per annum: Harrington Starr: Client Relationship Manager - SQL...
£35000 - £50000 per annum: Pro-Recruitment Group: Take your chance to join the...